4.6 Article

Noninvasive biomarkers identify eosinophilic esophagitis: A prospective longitudinal study in children

Journal

ALLERGY
Volume 76, Issue 12, Pages 3755-3765

Publisher

WILEY
DOI: 10.1111/all.14874

Keywords

biomarker; blood; eosinophil; eosinophilic esophagitis; noninvasive

Funding

  1. HOPE pilot grant from the American Partnership for Eosinophilic Disorders (APFED)
  2. Buckeye Foundation [K08DK097721]
  3. Ann & Robert H. Lurie Children's Hospital of Chicago
  4. Consortium of Eosinophilic Gastrointestinal Researchers (CEGIR)
  5. National Institute of Allergy and Infectious Disease
  6. National Institute of Diabetes, Digestive, and Kidney Diseases
  7. Nation Center for Advancing Translational Sciences
  8. American Partnership for Eosinophilic Disorders
  9. Campaign Urging Research for Eosinophilic Diseases
  10. Eosinophil Family Coalition

Ask authors/readers for more resources

Novel panels of eosinophil-associated proteins in blood and urine were found to help diagnose eosinophilic esophagitis (EoE) and predict esophageal eosinophilia. These biomarkers, combined with absolute eosinophil count (AEC), were superior to AEC alone in distinguishing EoE from controls and predicting esophageal eosinophil counts.
Background Esophageal histology is critical for diagnosis and surveillance of disease activity in eosinophilic esophagitis (EoE). A validated noninvasive biomarker has not been identified. We aimed to determine the utility of blood and urine eosinophil-associated proteins to diagnose EoE and predict esophageal eosinophilia. Methods Blood and urine were collected from children undergoing endoscopy with biopsy. Absolute eosinophil count (AEC), plasma eosinophil-derived neurotoxin (EDN), eosinophil cationic protein (ECP), major basic protein-1 (MBP-1), galectin-10 (CLC/GAL-10), Eotaxin-2 and Eotaxin-3, and urine osteopontin (OPN) and matrix metalloproteinase-9 (MMP-9) were determined. Differences were assessed between EoE and control, and with treatment response. The capacity to predict EoE diagnosis and esophageal eosinophil counts was assessed. Results Of 183 specimens were collected from 56 EoE patients and 15 non-EoE controls with symptoms of esophageal dysfunction; 33 EoE patients had paired pre- and post-treatment specimens. Plasma (CLC/GAL-10, ECP, EDN, Eotaxin-3, MBP-1) and urine (OPN) biomarkers were increased in EoE compared to control. A panel comprising CLC/GAL-10, Eotaxin-3, ECP, EDN, MBP-1, and AEC was superior to AEC alone in distinguishing EoE from control. AEC, CLC/GAL-10, ECP, and MBP-1 were significantly decreased in patients with esophageal eosinophil counts <15/hpf in response to treatment. AEC, CLC/GAL-10, ECP, EDN, OPN, and MBP-1 each predicted esophageal eosinophil counts utilizing mixed models controlled for age, gender, treatment, and atopy; AEC combined with MBP-1 best predicted the counts. Conclusions We identified novel panels of eosinophil-associated proteins that along with AEC are superior to AEC alone in distinguishing EoE from controls and predicting esophageal eosinophil counts.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available